| Study Details | TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA |
| Protocol Number | R3918-PNH-2050 |
| Phase | III |
| Therapeutic Area | Haematology |
| Subject Types | With Medical Condition |
| Indication | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Principal Investigator | Dr Yap Eng Soo |
| Investigator Product / Device | Pozelimab and Cemdisiran |
| Sponsor | Regeneron Pharmaceuticals, Inc. |
